PTPI 0.42 Petros Pharmaceuticals, Inc.
| Range: | 0.282-2.27 | Vol Avg: | 164939 | Last Div: | 0 | Changes: | 0 |
| Beta: | 2.31 | Cap: | 0.00B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Wed Dec 02 2020 | Empoloyees: | 21 | ||
| CUSIP: | 71678J100 | CIK: | 0001815903 | ISIN: | US71678J2096 | Country: | US |
| CEO: | Mr. Fady Boctor M.B.A. | Website: | https://www.petrospharma.com | ||||
Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a patented topical formulation candidate for the treatment of acute Peyronie's disease. The company markets its line of ED products in the form of vacuum erection device products. Petros Pharmaceuticals, Inc. is based in New York, New York.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow